Journal ArticleDOI
Antitumor activity of thalidomide in refractory multiple myeloma.
Seema Singhal,Jayesh Mehta,Raman Desikan,D Ayers,Paula K. Roberson,Paul Eddlemon,Nikhil C. Munshi,Elias Anaissie,Carla S. Wilson,Madhav V. Dhodapkar,J Zeddis,Bart Barlogie +11 more
Reads0
Chats0
TLDR
Thalidomide can induce marked and durable responses in some patients with multiple myeloma, including those who relapse after high-dose chemotherapy, and is active against advancedMyeloma.Abstract:
Background Patients with myeloma who relapse after high-dose chemotherapy have few therapeutic options. Since increased bone marrow vascularity imparts a poor prognosis in myeloma, we evaluated the efficacy of thalidomide, which has antiangiogenic properties, in patients with refractory disease. Methods Eighty-four previously treated patients with refractory myeloma (76 with a relapse after high-dose chemotherapy) received oral thalidomide as a single agent for a median of 80 days (range, 2 to 465). The starting dose was 200 mg daily, and the dose was increased by 200 mg every two weeks until it reached 800 mg per day. Response was assessed on the basis of a reduction of the myeloma protein in serum or Bence Jones protein in urine that lasted for at least six weeks. Results The serum or urine levels of paraprotein were reduced by at least 90 percent in eight patients (two had a complete remission), at least 75 percent in six patients, at least 50 percent in seven patients, and at least 25 percent in six p...read more
Citations
More filters
Journal ArticleDOI
Inflammation and cancer: back to Virchow?
TL;DR: A rationale for the use of cytokine and chemokine blockade, and further investigation of non-steroidal anti-inflammatory drugs, in the chemoprevention and treatment of malignant diseases is provided.
Journal ArticleDOI
A phase 2 study of bortezomib in relapsed, refractory myeloma.
Paul G. Richardson,Bart Barlogie,James R. Berenson,Seema Singhal,Sundar Jagannath,D. Irwin,S. Vincent Rajkumar,Gordan Srkalovic,Melissa Alsina,Raymond Alexanian,David S. Siegel,Robert Z. Orlowski,David J. Kuter,Steven Limentani,Stephanie J. Lee,Teru Hideshima,Dixie Lee Esseltine,Michael Kauffman,Julian Adams,David P. Schenkein,Kenneth C. Anderson +20 more
TL;DR: Bortezomib, a member of a new class of anticancer drugs, is active in patients with relapsed multiple myeloma that is refractory to conventional chemotherapy.
Journal ArticleDOI
Drug repurposing: progress, challenges and recommendations
Sudeep Pushpakom,Francesco Iorio,Patrick A. Eyers,K. Jane Escott,Shirley Hopper,Andrew D. Wells,Andrew J. Doig,Tim Guilliams,Joanna Latimer,Christine J. McNamee,Alan Norris,Philippe Sanseau,David Cavalla,Munir Pirmohamed +13 more
TL;DR: Approaches used for drug repurposing (also known as drug repositioning) are presented, the challenges faced by the repurpose community are discussed, and innovative ways by which these challenges could be addressed are recommended to help realize the full potential of drugRepurposing.
Journal ArticleDOI
Multiple myeloma
Noopur Raje,Kenneth C. Anderson +1 more
TL;DR: The use of bisphosphonates in patients with multiple myeloma (MM) has clearly demonstrated benefit and reduced morbidity associated with bone disease, but all patients with MM ultimately relapse and succumb to their disease.
Journal ArticleDOI
Improved survival in multiple myeloma and the impact of novel therapies
Shaji Kumar,S. Vincent Rajkumar,Angela Dispenzieri,Martha Q. Lacy,Suzanne R. Hayman,Francis K. Buadi,Steven R. Zeldenrust,David Dingli,Stephen J. Russell,John A. Lust,Philip R. Greipp,Robert A. Kyle,Morie A. Gertz +12 more
TL;DR: Improved outcome of patients with myeloma in recent years is demonstrated, both in the relapsed setting as well as at diagnosis, both from time of diagnosis and the time of relapse.
References
More filters
Book ChapterDOI
Nonparametric Estimation from Incomplete Observations
Edward L. Kaplan,Paul Meier +1 more
TL;DR: In this article, the product-limit (PL) estimator was proposed to estimate the proportion of items in the population whose lifetimes would exceed t (in the absence of such losses), without making any assumption about the form of the function P(t).
Journal ArticleDOI
Angiogenesis in cancer, vascular, rheumatoid and other disease
TL;DR: Think of the switch to the angiogenic phenotype as a net balance of positive and negative regulators of blood vessel growth, which may dictate whether a primary tumour grows rapidly or slowly and whether metastases grow at all.
Journal Article
Evaluation of survival data and two new rank order statistics arising in its consideration.
Journal ArticleDOI
A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Français du Myélome.
Michel Attal,Jean-Luc Harousseau,Anne-Marie Stoppa,Jean-Jacques Sotto,Jean-Gabriel Fuzibet,Jean-François Rossi,Philippe Casassus,Hervé Maisonneuve,Thierry Facon,Norbert Ifrah,Catherine Payen,Régis Bataille +11 more
TL;DR: The response rate among the patients who received high-dose therapy was 81 percent, whereas it was 57 percent in the group treated with conventional chemotherapy (P<0.001).
Journal ArticleDOI
Thalidomide is an inhibitor of angiogenesis.
TL;DR: Electron microscopic examination of the corneal neovascularization of thalidomide-treated rabbits revealed specific ultrastructural changes similar to those seen in the deformed limb bud vasculature of Thalidomid-treated embryos.
Related Papers (5)
A phase 2 study of bortezomib in relapsed, refractory myeloma.
Paul G. Richardson,Bart Barlogie,James R. Berenson,Seema Singhal,Sundar Jagannath,D. Irwin,S. Vincent Rajkumar,Gordan Srkalovic,Melissa Alsina,Raymond Alexanian,David S. Siegel,Robert Z. Orlowski,David J. Kuter,Steven Limentani,Stephanie J. Lee,Teru Hideshima,Dixie Lee Esseltine,Michael Kauffman,Julian Adams,David P. Schenkein,Kenneth C. Anderson +20 more
Thalidomide and its analogs overcome drug resistance of human multiple myeloma cells to conventional therapy.
Teru Hideshima,Dharminder Chauhan,Dharminder Chauhan,Yoshihito Shima,Yoshihito Shima,Noopur Raje,Noopur Raje,Faith E. Davies,Faith E. Davies,Yu-Tzu Tai,Yu-Tzu Tai,Steven P. Treon,Steven P. Treon,Boris Lin,Boris Lin,Robert L. Schlossman,Robert L. Schlossman,Paul G. Richardson,Paul G. Richardson,George W. Muller,George W. Muller,David I. Stirling,David I. Stirling,Kenneth C. Anderson,Kenneth C. Anderson +24 more
Bortezomib or high-dose dexamethasone for relapsed multiple myeloma
Paul G. Richardson,Pieter Sonneveld,Michael W. Schuster,D. Irwin,Edward A. Stadtmauer,Thierry Facon,Jean-Luc Harousseau,Dina Ben-Yehuda,Sagar Lonial,Hartmut Goldschmidt,Donna E. Reece,Jesús F. San-Miguel,Joan Bladé,Mario Boccadoro,Jamie Cavenagh,William S. Dalton,Anthony Boral,Dixie Lee Esseltine,Jane B. Porter,David P. Schenkein,Kenneth C. Anderson +20 more